The first injection of the world that triggers the programmed death of adipose cells in a specific area, such as the belly or the thighs, is one step from the approval of the Food and Drug Administration (FDA) from the USA.
What if it were possible to inject a medicine into a “problem area” that could reduce fat reserves at a localized point?
This is precisely what offers a new Caliway Pharmaceuticals in Taiwan medicine. It is announced as the First injection of the world that triggers the programmed death of adipose cells in a specific area.
O CBL-514 It induces apoptosis of adipocytes, which kills adipose cells instead of letting them die hungry, which means different regions of subcutaneous fat reserves can be quickly reduced in just a few weeks after a single dose.
As detailed to, this medicine is being tested for three uses: non -surgical reduction in fat; DERCUM DISEASE – which causes the formation of painful fatty tumors throughout the body; and cellulite.
About to be approved by FDA
The CBL-514 successfully completed two phase 2b studies (CBL-0204 and CBL-0205) and is about to hold two global clinical trials of phase 3 in the second half of 2025.
No, 75% saw their abdominal fat reduced by at least one degree on the abdominal fat classification scale (AFRs) four weeks after the initial single injection.
This means that passed its effectiveness parameter to satisfy the FDAwhich had already demonstrated (along with security and tolerability) in the previous 2B test.
In 2023, the FDA approved the CBL-514 as a new investigative drug. A year later, he was approved by the European Medicines Agency (EMA), receiving the orphan drug designation status for the treatment of Dercum disease – a condition characterized by the development of (benign fats of fat in subcutaneous tissue.
In May, the company obtained the seal of approval to move to the final phase of clinical trials. If successful in these larger tests, may be on the market within 12 months.
At this time, the only approved medicine to reduce localized fat is the ATX-101-or injection of deoxycholic acid-which has been effective in reducing adipose reserves in small areas, but has severe side effects, including skin necrosis, ulceration, nerve injuries and infections.
However, the CBL-514 did not cause any of these problems, even with multiple doses in much larger areas of the body.
Although it has an obvious aesthetic application – non -surgical body sculpture – the first drug in its class has wider benefits.
Abdominal fat, especially in mid-aged and later in life, has been implied in a series of serious diseases, including chronic painstroke (AVC) e cardiovascular diseases.
